Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

Don the Purple for Epilepsy Awareness in November

Sporting purple gear and sharing personal stories, supporters are observing National Epilepsy Awareness Month in November to call attention to epilepsy and associated disorders, such as Dravet and Lennox-Gastaut syndromes. More than 65 million individuals globally live with the central nervous system disorder. One-third of those experience…

$17.5M CDC Award to Help Develop Public Health System for Epilepsy

To establish a public health infrastructure that advances health equity and improves the lives of people with epilepsy, the Centers for Disease Control and Prevention (CDC) has awarded $17.5 million to the Epilepsy Foundation and its partners. The five-year award will support efforts by these organizations to establish and sustain…

New Program Supports Siblings of Rare Epilepsy Patients

Siblings of children with Dravet syndrome often grow up “in an environment permeated by stress, anxiety, and fear for their loved one’s well-being,” according to the biopharmaceutical company Zogenix. Now, a new online resource is available to help support the brothers and sisters of patients with severe rare epilepsies.

EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes

To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…

Zogenix Opens Photo Contest to Benefit Advocacy Groups

The biopharmaceutical company Zogenix is introducing a Dravet syndrome community photo-sharing campaign and contest to benefit the Dravet Syndrome Foundation and the Epilepsy Foundation. U.S. families of Dravet patients whose seizures are treated with Fintepla (fenfluramine) — an add-on therapy developed by Zogenix — may enter the…